Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Cash from Financing Activities (2016 - 2026)

Apyx Medical filings provide 15 years of Cash from Financing Activities readings, the most recent being $9.5 million for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 40.31% to $9.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.6 million, a 42.03% increase, with the full-year FY2025 number at $9.6 million, up 42.03% from a year prior.
  • Cash from Financing Activities hit $9.5 million in Q4 2025 for Apyx Medical, up from $45000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $23.8 million in Q4 2023 to a low of -$61000.0 in Q1 2021.
  • Median Cash from Financing Activities over the past 5 years was $35000.0 (2025), compared with a mean of $2.4 million.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 506.67% in 2021 and later surged 238540.0% in 2023.
  • Apyx Medical's Cash from Financing Activities stood at -$39000.0 in 2021, then surged by 74.36% to -$10000.0 in 2022, then surged by 238540.0% to $23.8 million in 2023, then crashed by 71.65% to $6.8 million in 2024, then surged by 40.31% to $9.5 million in 2025.
  • The last three reported values for Cash from Financing Activities were $9.5 million (Q4 2025), $45000.0 (Q3 2025), and $25000.0 (Q2 2025) per Business Quant data.